U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-QSB
(Mark One)
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934
For the quarterly period ended June 30, 2003
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the transition period from _____ to _______
Commission file number 0-27239
GENEMAX CORP.
_________________________________________________________________
(Exact name of small business issuer as specified in its charter)
NEVADA 88-0277072
_______________________________ ___________________
(State or other jurisdiction of (I.R.S. Employer
incorporation of organization) Identification No.)
435 Martin Street, Suite 2000
Blaine, Washington 98230
________________________________________
(Address of Principal Executive Offices)
(360) 332-7734
___________________________
(Issuer's telephone number)
N/A
____________________________________________________
(Former name, former address and former fiscal year,
if changed since last report)
Check whether the issuer (1) filed all reports required to be filed by Section
13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter
period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days.
Yes [X] No [ ]
State the number of shares outstanding of each of the issuer's classes of common
equity, as of the latest practicable date:
Class Outstanding as of August 11, 2003
______________________________ _________________________________
Common Stock, $0.001 par value 16,813,519
Transitional Small Business Disclosure Format (check one)
Yes [ ] No [X]
PART I. FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
INTERIM CONSOLIDATED BALANCE SHEETS 2
INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS 3
INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS 4
NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS 5
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION OR PLAN OF OPERATION
ITEM 3. CONTROLS AND PROCEDURES
PART II. OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS 13
ITEM 2. CHANGES IN SECURITIES AND USE OF PROCEEDS 13
ITEM 3. DEFAULTS UPON SENIOR SECURITIES 14
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS 14
ITEM 5. OTHER INFORMATION 14
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K 14
SIGNATURES 15
PART 1. FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
____________________________
GENEMAX CORP.
(A DEVELOPMENT STAGE COMPANY)
INTERIM CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 2003
(UNAUDITED)
CONSOLIDATED BALANCE SHEETS
INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS
INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS
NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS
GENEMAX CORP.
(A DEVELOPMENT STAGE COMPANY)
INTERIM CONSOLIDATED BALANCE SHEETS
June 30, December 31,
2003 2002
_______________________________________________________________________________________________________________________________
(unaudited)
ASSETS
CURRENT ASSETS
Cash $ 46,204 $ 642,589
Prepaid expenses 6,000 6,000
_______________________________________________________________________________________________________________________________
52,204 648,589
FURNITURE AND EQUIPMENT, (Note 5)
net of depreciation of $100,551 (2002 - $79,138) 92,232 112,839
_______________________________________________________________________________________________________________________________
$ 144,436 $ 761,428
===============================================================================================================================
LIABILITIES AND STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)
CURRENT LIABILITIES
Accounts payable and accrued liabilities $ 492,927 $ 264,613
Due to related parties (Note 6) 311,155 30,986
_______________________________________________________________________________________________________________________________
804,082 295,599
_______________________________________________________________________________________________________________________________
COMMITMENTS AND CONTINGENCIES (Notes 1, 4 and 6)
STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)
Capital stock (Note 7)
Common stock, $0.001 par value, 25,000,000 shares authorized
16,813,519 shares issued and outstanding (2002 - 15,847,519) 16,813 15,847
Additional paid-in capital 4,876,199 3,621,665
Common stock subscriptions - 200,000
Common stock purchase warrants 610,700 610,700
Deficit accumulated during the development stage (6,127,799) (3,972,760)
Accumulated other comprehensive income (loss) (35,559) (9,623)
_______________________________________________________________________________________________________________________________
(659,646) 465,829
_______________________________________________________________________________________________________________________________
$ 144,436 $ 159,470
===============================================================================================================================
The accompanying notes are an integral part of these interim consolidated financial statements
GENEMAX CORP.
(A DEVELOPMENT STAGE COMPANY)
INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)
July 27, 1999
(inception) to
Three months ended June 30, Six months ended June 30, June 30,
2003 2002 2003 2002 2003
__________________________________________________________________________________________________________________________________
(Note 1) (Note 1) (Note 1)
INTEREST INCOME $ - $ 29 $ - $ 29 $ 26,571
OTHER INCOME
__________________________________________________________________________________________________________________________________
EXPENSES
Consulting fees 28,718 6,014 84,718 35,500 438,995
Consulting fees - stock based (Note 8) 549,625 - 561,500 - 1,191,775
Depreciation 10,731 10,180 21,413 20,361 100,551
License fees - - - - 79,243
Management fees 56,844 27,322 111,690 60,322 598,896
Office and general 244,589 22,792 610,346 41,803 857,772
Professional fees 68,444 45,213 154,198 72,249 664,701
Research and development 293,871 249,992 568,647 362,641 2,101,687
Travel 27,569 503 42,527 1,821 120,750
__________________________________________________________________________________________________________________________________
1,280,391 362,016 2,155,039 594,697 6,154,370
__________________________________________________________________________________________________________________________________
NET LOSS FOR THE PERIOD $(1,280,391) $ (361,987) $(2,155,039) $ (594,668) $(6,127,799)
==================================================================================================================================
BASIC NET LOSS PER SHARE $ (0.08) $ (0.03) $ (0.13) $ (0.05)
=================================================================================================================
WEIGHTED AVERAGE COMMON
SHARES OUTSTANDING 16,813,123 11,431,965 16,535,591 11,431,965
=================================================================================================================
The accompanying notes are an integral part of these interim consolidated financial statements
GENEMAX CORP.
(A DEVELOPMENT STAGE COMPANY)
INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
July 27, 1999
(inception) to
Six months Ended June 30 June 30,
2003 2002 2003
_______________________________________________________________________________________________________________________________
(Note 1) (Note 1)
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss for the period $ (2,155,039) $ (594,668) $ (6,127,799)
Adjustments to reconcile net loss to net cash from operating activities:
- depreciation 21,413 20,361 100,551
- non-cash consulting fees - - 5,750
- non-cash license fees - - 500
- stock-based compensation 561,500 - 1,191,775
- accounts payable 228,314 100,480 478,643
_______________________________________________________________________________________________________________________________
NET CASH USED IN OPERATING ACTIVITIES (1,343,812) (473,827) (4,350,580)
_______________________________________________________________________________________________________________________________
CASH FLOWS FROM (USED IN) INVESTING ACTIVITIES
Purchase of furniture and equipment (806) - (192,783)
Pre reverse acquisition advances from Eduverse (Note 3) - 250,000 250,000
Cash acquired on reverse acquisition of Eduverse (Note 3) - 173,373
_______________________________________________________________________________________________________________________________
NET CASH FROM (USED IN) INVESTING ACTIVITIES (806) 250,000 230,590
_______________________________________________________________________________________________________________________________
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds on sale and subscriptions of common stock 494,000 170,500 3,675,730
Loans payable - 68,545 136,245
Advances from related parties 280,169 107,343 389,778
_______________________________________________________________________________________________________________________________
NET CASH FLOWS FROM FINANCING ACTIVITIES 774,169 346,388 4,201,753
_______________________________________________________________________________________________________________________________
EFFECT OF EXCHANGE RATE CHANGES (25,936) (5,301) (35,559)
_______________________________________________________________________________________________________________________________
INCREASE (DECREASE) IN CASH (596,385) 117,260 46,204
CASH, BEGINNING OF PERIOD 642,589 11,561 -
_______________________________________________________________________________________________________________________________
CASH, END OF PERIOD $ 46,204 $ 128,821 $ 46,204
===============================================================================================================================
The accompanying notes are an integral part of these interim consolidated financial statements
GENEMAX CORP.
(A DEVELOPMENT STAGE COMPANY)
NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 2003
________________________________________________________________________________
(UNAUDITED)
NOTE 1 - NATURE OF OPERATIONS AND BASIS OF PRESENTATION
________________________________________________________________________________
On May 9, 2002, GeneMax Corp. (formerly Eduverse.com) ("GMC", "Eduverse" or
"the Company"), a Nevada corporation entered into a letter of intent to acquire
100% of the issued and outstanding common shares of GeneMax Pharmaceuticals Inc.
(a development stage company) ("GPI"), in exchange for a total of 11,431,965
restricted shares of common stock of Eduverse. In connection with this
transaction, Eduverse changed its name to GeneMax Corp. During July and August
Eduverse completed the transaction pursuant to a definitive Share Exchange
Agreement and issued 11,231,965 restricted shares of common stock to the GPI
stockholders and 200,000 shares of common stock as a finder's fee.
This acquisition has been accounted for as a reverse merger with GPI being
treated as the accounting parent and GMC, the legal parent, being treated as the
accounting subsidiary. Accordingly, the consolidated results of operations of
the Company include those of GPI for all periods shown and those of GMC since
the date of the reverse merger.
GPI is a private Delaware company incorporated July 27, 1999 which has a
wholly-owned subsidiary, GeneMax Pharmaceuticals Canada Inc. ("GPC"), a private
British Columbia company incorporated May 12, 2000. GPI is a development stage
company which was formed for the purpose of building a biotechnology business
specializing in the discovery and development of immunotherapeutics aimed at the
treatment and eradication of cancer, and therapies for infectious diseases,
autoimmune disorders and transplant tissue rejection.
During 2000 GPI and the University of British Columbia ("UBC") entered into a
world-wide license agreement providing GPI the exclusive license rights to
certain patented and unpatented technologies originally invented and developed
by UBC. Also during 2000 GPI and UBC entered into a Collaborative Research
Agreement ("CRA") appointing UBC to carry out further development of the
licensed technology and providing GPI the option to acquire the rights to
commercialize any additional technologies developed within the CRA in
consideration for certain funding commitments (Refer to Note 4).
The consolidated financial statements have been prepared on the basis of a going
concern which contemplates the realization of assets and the satisfaction of
liabilities in the normal course of business. The Company has a working capital
deficiency of $751,878, a capital deficiency of $659,646 and has incurred
significant losses since inception and further losses are anticipated in the
development of its products raising substantial doubt as to the Company's
ability to continue as a going concern. The ability of the Company to continue
as a going concern is dependent on raising additional capital to fund ongoing
research and development and ultimately on generating future profitable
operations.
UNAUDITED INTERIM FINANCIAL STATEMENTS
The accompanying unaudited interim consolidated financial statements have been
prepared in accordance with generally accepted accounting principles for interim
financial information and conforms with instructions to Form 10-QSB of
Regulation S-B. They may not include all information and footnotes required by
generally accepted accounting principles for complete financial statements.
However, except as disclosed herein, there has been no material changes in the
information disclosed in the notes to the financial statements for the year
ended December 31, 2002 included in the Company's Annual Report on Form 10-KSB
filed with the Securities and Exchange Commission. The interim unaudited
financial statements should be read in conjunction with those financial
statements included in the Form 10-KSB. In the opinion of Management, all
adjustments considered necessary for a fair presentation, consisting solely of
normal recurring adjustments, have been made. Operating results for the six
months ended June 30, 2003 are not necessarily indicative of the results that
may be expected for the year ending December 31, 2003.
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
________________________________________________________________________________
BASIS OF PRESENTATION
These consolidated financial statements have been presented in United States
dollars and prepared in accordance with United States Generally Accepted
Accounting Principles ("US GAAP").
GENEMAX CORP.
(A DEVELOPMENT STAGE COMPANY)
NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 2003
________________________________________________________________________________
(UNAUDITED)
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT'D)
________________________________________________________________________________
PRINCIPLES OF CONSOLIDATION
The financial statements include the accounts of the Company and its
wholly-owned subsidiaries GPI and GPC as described in Notes 1 and 3. The
consolidated financial statements also include the accounts of the Company's
inactive wholly-owned subsidiary, M&M Information and Marketing Services Inc.
(incorporated in Nevada, USA). All significant intercompany balances and
transactions are eliminated on consolidation.
USE OF ESTIMATES AND ASSUMPTIONS
Preparation of the Company's financial statements in conformity with United
States generally accepted accounting principles requires management to make
estimates and assumptions that affect certain reported amounts and disclosures.
Accordingly, actual results could differ from those estimates.
FURNITURE AND EQUIPMENT
Furniture and equipment are stated at cost. Depreciation is computed at the
following rates over the estimated useful lives of the assets:
Office furniture and equipment 36 months straight-line
Laboratory equipment 60 months straight-line
RESEARCH AND DEVELOPMENT COSTS
The Company has acquired exclusive development and marketing rights to certain
technologies through a License Agreement and a Collaborative Research Agreement
with UBC. The rights and license acquired are considered rights to unproven
technology which may not have alternate future uses and therefore, have been
expensed as incurred as research and development costs. Also, ongoing costs
incurred in connection with the Collaborative Research Agreement are considered
costs incurred in the development of unproven technology which may not have
alternate future uses and therefore, have been expensed as incurred as research
and development costs.
FAIR VALUE OF FINANCIAL INSTRUMENTS
In accordance with the requirements of SFAS No. 107, the Company has determined
the estimated fair value of financial instruments using available market
information and appropriate valuation methodologies. The fair value of financial
instruments classified as current assets or liabilities including cash, prepaid
expense, loans and accounts payable and due to related parties approximate
carrying value due to the short-term maturity of the instruments.
FOREIGN CURRENCY TRANSLATION
The financial statements are presented in United States dollars. In accordance
with Statement of Financial Accounting Standards No. 52, "Foreign Currency
Translation", foreign denominated monetary assets and liabilities are translated
to their United States dollar equivalents using foreign exchange rates which
prevailed at the balance sheet date. Revenue and expenses are translated at
average rates of exchange during the year. Related translation adjustments are
reported as a separate component of stockholders' equity, whereas gains or
losses resulting from foreign currency transactions are included in results of
operations.
NET LOSS PER COMMON SHARE
Basic earnings (loss) per share includes no dilution and is computed by dividing
income available to common stockholders by the weighted average number of common
shares outstanding for the period. Dilutive earnings (loss) per share reflect
the potential dilution of securities that could share in the earnings of the
Company. The accompanying presentation is only of basic loss per share as the
potentially dilutive factors are anti-dilutive to basic loss per share.
GENEMAX CORP.
(A DEVELOPMENT STAGE COMPANY)
NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 2003
________________________________________________________________________________
(UNAUDITED)
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT'D)
________________________________________________________________________________
STOCK-BASED COMPENSATION
In December 2002, the Financial Accounting Standards Board issued Financial
Accounting Standard No. 148, "Accounting for Stock-Based Compensation -
Transition and Disclosure" ("SFAS No. 148"), an amendment of Financial
Accounting Standard No. 123 "Accounting for Stock-Based Compensation" ("SFAS No.
123"). The purpose of SFAS No. 148 is to: (1) provide alternative methods of
transition for an entity that voluntarily changes to the fair value based method
of accounting for stock-based employee compensation, (2) amend the disclosure
provisions to require prominent disclosure about the effects on reported net
income of an entity's accounting policy decisions with respect to stock-based
employee compensation, and (3) to require disclosure of those effects in interim
financial information. The disclosure provisions of SFAS No. 148 were effective
for the Company for the year ended December 31, 2002. As the options granted
during the period were to consultants, no pro forma disclosures are required.
The Company has elected to continue to account for stock-based employee
compensation arrangements in accordance with the provisions of Accounting
Principles Board Opinion No. 25, "Accounting for Stock Issued to Employees",
("APB No. 25") and comply with the disclosure provisions of SFAS No. 123 as
amended by SFAS No. 148 as described above. In addition, in accordance with SFAS
No. 123 the Company applies the fair value method using the Black-Scholes
option-pricing model in accounting for options granted to consultants. Under APB
No. 25, compensation expense is recognized based on the difference, if any, on
the date of grant between the estimated fair value of the Company's stock and
the amount an employee must pay to acquire the stock. Compensation expense is
recognized immediately for past services and pro-rata for future services over
the option-vesting period.
In accordance with SFAS No. 123, the Company applies the fair value method using
the Black-Scholes option-priceing model in accounting for options granted to
consultants.
The Company accounts for equity instruments issued in exchange for the receipt
of goods or services from other than employees in accordance with SFAS No. 123
and the conclusions reached by the Emerging Issues Task Force in Issue No.
96-18, "Accounting for Equity Instruments That Are Issued to Other Than
Employees for Acquiring or in Conjunction with Selling Goods or Services" ("EITF
96-18"). Costs are measured at the estimated fair market value of the
consideration received or the estimated fair value of the equity instruments
issued, whichever is more reliably measurable. The value of equity instruments
issued for consideration other than employee services is determined on the
earlier of a performance commitment or completion of performance by the provider
of goods or services as defined by EITF 96-18.
The Company has also adopted the provisions of the Financial Accounting
Standards Board Interpretation No.44, Accounting for Certain Transactions
Involving Stock Compensation - An Interpretation of APB Opinion No. 25 ("FIN
44"), which provides guidance as to certain applications of APB 25. FIN 44 is
generally effective July 1, 2000 with the exception of certain events occurring
after December 15, 1998.
GENEMAX CORP.
(A DEVELOPMENT STAGE COMPANY)
NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 2003
________________________________________________________________________________
(UNAUDITED)
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT'D)
________________________________________________________________________________
INCOME TAXES
The Company follows the liability method of accounting for income taxes. Under
this method, deferred income tax assets and liabilities are recognized for the
estimated tax consequences attributable to differences between the financial
statement carrying values and their respective income tax basis (temporary
differences). The effect on deferred income tax assets and liabilities of a
change in tax rates is recognized in income in the period that includes the
enactment date. At June 30, 2003 a full deferred tax asset valuation allowance
has been provided and no deferred tax asset benefit has been recorded.
NOTE 3 - EDUVERSE ACQUISITION
________________________________________________________________________________
Effective May 9, 2002 the Company entered into a letter of intent to acquire
100% of the issued shares in the capital of GPI in exchange for 11,231,965
restricted shares of common stock plus 200,000 restricted shares of common stock
for a finder's fee. The Company also agreed to issue an additional 188,154
restricted shares of common stock in settlement of $188,154 of accrued GPI
management, consulting and research and development fees. Effective July 15,
2002, pursuant to a definitive Share Exchange Agreement, the Company commenced
the closing and acquired 5,880,304 shares of GPI from non-British Columbia
shareholders of GPI in exchange for the issuance of 5,880,304 restricted shares
of common stock. The Company also issued a take-over bid circular to British
Columbia GPI shareholders and acquired a further 4,487,001 shares of GPI in
exchange for 4,487,001 restricted shares of common stock effective August 13,
2002. Also during the 2002, the Company completed the acquisition by acquiring
the remaining 864,660 shares of GPI in exchange for 864,660 restricted shares of
common stock. Also, 744,494 outstanding GPI common stock purchase warrants were
exchanged on a one for one basis for the Company's common stock purchase
warrants with identical terms and conditions and the Company issued 2,135,000
stock options to holders of GPI stock options (refer to Note 8). All GPI stock
options and common stock purchase warrants were then cancelled. As a result of
this transaction, the former stockholders of GPI owned 75% of the 15,320,119
total issued and outstanding shares of the Company as at July 15, 2002. In
connection with this transaction, Eduverse changed its name to GeneMax Corp
("GMC").
This acquisition has been accounted for as a recapitalization using accounting
principles applicable to reverse acquisitions with GPI being treated as the
accounting parent (acquirer) and GMC being treated as the accounting subsidiary
(acquiree). The value assigned to the capital stock of consolidated GMC on
acquisition of GPI is equal to the book value of the capital stock of GPI plus
the book value of the net assets of GMC as at the date of the acquisition.
The book value of GMC's capital stock subsequent to the reverse acquisition is
calculated and allocated as follows:
GPI capital stock $ 1,924,725
GMC net assets 493,712
_________________
$ 2,418,437
=================
Capital stock $ 15,320
Additional paid-in capital 620,600
Share purchase warrants 1,867,517
_________________
2,503,437
GMC subscriptions receivable pre reverse acquisition (100,000)
GMC subscriptions received pre reverse acquisition 15,000
_________________
Consolidated Capital accounts post reverse acquisition $ 2,418,437
=================
GENEMAX CORP.
(A DEVELOPMENT STAGE COMPANY)
NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 2003
________________________________________________________________________________
(UNAUDITED)
NOTE 3 - EDUVERSE ACQUISITION (CONT'D)
________________________________________________________________________________
These consolidated financial statements include the results of operations of GPI
since July 27, 1999 (inception) and the results of operations of GMC since the
date of the reverse merger effective July 15, 2002. GMC'S results of operations
for the period from January 1, 2002 to June 30, 2002 have been reported in the
Company's June 30, 2002 filing on Form 10-QSB.
For the period from October 13, 1999 (inception) to July 14, 2002 the weighted
average number of common shares outstanding is deemed to be 11,431,965 being the
number of shares issued by GMC (including 200,000 common shares issued as
finders' fees) to effect the reverse acquisition of GPI.
NOTE 4 - RESEARCH AGREEMENTS
________________________________________________________________________________
UNIVERSITY OF BRITISH COLUMBIA ("UBC")
Effective September 14, 1999 GPI entered into an Option Agreement ("Option")
whereby UBC granted GPI an option to obtain a world-wide license from UBC
providing GPI the exclusive license rights to certain patented and unpatented
cancer immuno-therapy technologies originally invented and developed by UBC. The
Option was for a term of 180 days and was considered exercised upon execution of
the License Agreement with UBC as described below. Prior to being eligible to
exercise the Option, GPI was to make a reasonable commercial effort to raise
equity funding in an amount not less than CAN$1,000,000 to fund ongoing research
and issue 500,000 common shares to UBC and an additional 3,600,000 common shares
to certain principals involved in the UBC research.
Effective March 6, 2000, having satisfied the conditions of the Option, GPI
obtained from UBC, the exclusive license rights as described above for
consideration of $78,743. The License will terminate after 15 years or upon the
expiration of the last patent obtained relating to the licensed technology. The
cost of obtaining any patents will be the responsibility of GPI. The technology
remains the property of UBC, however, it may be utilized and improved by GPI.
Concurrent with the execution of the license the head researcher at UBC became a
director of GPI.
GPI and UBC entered into a Collaborative Research Agreement ("CRA") dated
September 1, 2000 appointing UBC to carry out further development of the
licensed technology and providing GPI the option to acquire the rights to
commercialize any additional technologies developed within the CRA in
consideration for certain funding commitments totalling CAN$498,980 to be paid
in four equal instalments of CAN$124,725 due upon execution of the CRA,
September 30, 2000, January 1, 2001 and March 31, 2001 of which $374,215 was
paid. Through a series of amendments between November 28, 2000 and September 9,
2002, the funding commitment was increased to a total of CAN$ 2,973,049 of which
CAN$991,515 was to be paid for the year ended December 31, 2002, CAN$1,135,801
to be paid in 2003 and CAN$471,518 to be paid in 2004. As at June 30, 2003
CAN$433,677 (December 31, 2002 - CAN$115,303) is payable in connection with the
CRA. In addition, as required by the CRA, GPI has purchased certain laboratory
equipment in connection with the ongoing research.
CANADIAN NETWORK FOR VACCINES AND IMMUNOTHERAPEUTICS OF CANCER AND CHRONIC VIRAL
DISEASES ("CANVAC")
Effective January 1, 2001 GPI and UBC entered into a one year Network Affiliate
Agreement with CANVAC (the "CANVAC Agreement") whereby CANVAC would provide a
grant to GPI and UBC to further fund the research activities in connection with
the CRA. Under the terms of the CANVAC Agreement, CANVAC would provide a
CAN$85,000 research grant to UBC upon GPI contributing CAN$117,300 towards the
UBC research. The amounts paid by GPI do not qualify as amounts paid under the
CRA funding schedule outlined above. During 2001, all amounts required under the
CANVAC agreement were paid to UBC by GPI. During 2002 CANVAC contributed a
further CAN$ $56,100 to continue funding the research activities for 2002 and
2003. As at June 30, 2003 GPI owes CAN$38,709 to UBC to fund GPI's obligations
under the CANVAC Agreement.
GENEMAX CORP.
(A DEVELOPMENT STAGE COMPANY)
NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 2003
________________________________________________________________________________
(UNAUDITED)
NOTE 5 - FURNITURE AND EQUIPMENT
________________________________________________________________________________
June 30, December 31,
2003 2002
__________________________________
Office furniture and equipment $ 32,839 $ 32,033
Laboratory equipment 159,944 159,944
__________________________________
192,783 191,977
Less: accumulated depreciation (100,551) (79,138)
__________________________________
$ 92,232 $ 112,839
==================================
NOTE 6 -RELATED PARTY TRANSACTIONS
________________________________________________________________________________
During 1999 and 2000 GPI entered into consulting, management and research and
development agreements with certain directors and private companies controlled
by directors of the Company. These agreements have terms ranging from month to
month to five years. In addition, in connection with the reverse merger, the
Company entered into a management services agreement with Investor
Communications, Inc. ("ICI"), a significant shareholder, whereby ICI will
provide various corporate services on a month-by-month basis for a fee of
$10,000 per month plus expenses. The following amounts have been incurred to
these related parties:
For the six months ended June 30,
2003 2002
____________________________________
Consulting fees $ 31,000 $ 33,000
Management fees 111,690 60,322
Research and development 66,184 76,268
____________________________________
$ 208,874 $ 169,590
=====================================
The Company has total commitments relating to the above agreements for the years
ended December 31, 2003 through 2005 of $192,000, $149,000 and $7,400
respectively.
A director of the Company has been contracted by ICI and is part of the
management team provided to the Company and was paid $19,625 during the six
months ended June 30, 2003.
During the six months ended June 30, 2003 GPI and the Company incurred $208,874
(2002 - $169,590) in fees and $601,412 (2002 - $NIL) in expense reimbursements
to these related parties, made net repayments of $530,117 (2002 - $62,247)
leaving $311,155 owing at June 30, 2003 (December 31, 2002 - $30,986). Amounts
due to related parties are unsecured, non-interest bearing and have no specific
terms of repayment.
Refer to Notes 3, 4 and 7.
NOTE 7 - CAPITAL STOCK
________________________________________________________________________________
The authorized capital of the Company consists of 50,000,000 voting common
shares with $0.001 par value and 5,000,000 non-voting preferred shares with
$.001 par value.
GENEMAX CORP.
(A DEVELOPMENT STAGE COMPANY)
NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 2003
________________________________________________________________________________
(UNAUDITED)
NOTE 7 - CAPITAL STOCK (CONT'D)
________________________________________________________________________________
GMC CAPITAL STOCK TRANSACTIONS DURING THE PERIOD ENDED JUNE 30, 2003:
During the period the Company issued 898,000 shares of common stock on the
exercise of stock options at $0.50 per share for proceeds of $449,000 and issued
25,000 shares of common stock on the exercise of stock options at $1.00 per
share for proceeds of $25,000.
During 2002 the Company commenced a private placement of up to 1,000,000 units
at $5.00 per unit. Each unit consists of one common share and one half share
purchase warrant. Each whole share purchase warrant will entitle the holder to
purchase an additional common share of the Company at a price of $7.50 per share
for a period of one year. During the period the Company issued 43,000 shares of
common stock on the purchase of 43,000 units for total proceeds of $215,000 of
which $185,000 had been received as at December 31, 2002 and $30,000 was
received during the period.
During the period the Company paid $10,000 in connection with the settlement of
$15,000 of subscriptions received in 2000 which were under dispute. As a result
of the settlement the Company recorded a contribution to additional paid in
capital in period of $5,000 and has been released from any further claims
relating to this matter.
GPI CAPITAL STOCK TRANSACTIONS DURING THE PERIOD ENDED JUNE 30, 2002:
During the period ended June 30, 2002 GPI completed private placements of
187,500 units at $1.00 per unit for total proceeds of $170,500, net of finder's
fees of $17,000. Each unit consists of one common share of the Company and one
share purchase warrant entitling the holder to purchase one additional common
share of the Company at a price of $1.00 per share with 12,500 of the warrants
expiring December 1, 2005 and 175,000 of the warrants expiring May 1, 2006.
STOCK OPTIONS
The Company accounts for stock-based employee compensation arrangements in
accordance with the provisions of APB No. 25 and complies with the disclosure
provisions of SFAS No. 123 and SFAS No. 148. In accordance with SFAS No. 123 the
Company applies the fair value method using the Black-Scholes option-pricing
model in connection with accounting for options granted to consultants and the
disclosure provision relating to options granted to employees
STOCK OPTION PLAN
On September 30, 2002 the Board of Directors of the Company approved the
adoption of a new stock option plan (the "Plan") allowing for the granting of up
to 3,500,000 options to directors, officers, employees and consultants of the
Company and its subsidiaries. Options granted under the Plan shall be at prices
and for terms as determined by the Board of Directors with terms not to exceed
10 years. The Plan further provides that the Board of Directors may grant to any
key personnel of the Company who is eligible to receive options, one or more
Incentive Stock Options at a price not less than fair market value and for a
period not to exceed 10 years from the date of grant. Options and Incentive
Stock Options granted under the Plan may have vesting requirements as determined
by the Board of Directors.
During the period, the Board of Directors approved an increase in the number of
options available under the Plan from 3,500,000 to 4,500,000.
The Plan incorporates a previous grant of 1,000,000 options to ICI and or its
designates or employees. During 2002 102,000 of these options were exercised at
$0.50 per share for proceeds of $51,000. During the period 898,000 of these
options were exercised at $0.50 per share for proceeds of $448,000.
In connection with the reverse acquisition as described in Note 3, the Company
granted 1,740,000 options and 245,000 incentive stock options at $1.00 per share
to previous holders of stock options of GPI to replace options previously
granted by GPI at $0.60 per share. In accordance with accounting principles
applicable to accounting for business combinations, the fair value of the stock
options granted in connection with a business combination is included in the
determination of the purchase price. The fair value of these options at the date
of grant of $1,885,750 was estimated using the Black-Scholes option pricing
model with an expected life of three years, a risk-free interest rate of 4% and
an expected volatility of 226%
GENEMAX CORP.
(A DEVELOPMENT STAGE COMPANY)
NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 2003
________________________________________________________________________________
(UNAUDITED)
NOTE 7 - CAPITAL STOCK (CONT'D)
________________________________________________________________________________
In addition, also in connection with the reverse acquisition as described in
Note 3, the Company granted 150,000 incentive stock options to previous holders
of stock options of GPI with terms and conditions consistent with their original
GPI stock options subject to straight line vesting for a period of 36 months
commencing October 1, 2002. The fair value of these incentive stock options will
be recorded as compensation expense over the vesting period. The fair value of
these options at the date of grant of $142,500 was estimated using the
Black-Scholes option pricing model with an expected life of three years, a
risk-free interest rate of 4% and an expected volatility of 226%. To June 30,
2003 a total of $35,625 (December 31, 2002 - $11,875) has been recorded as
consulting fees in connection with these options.
During the remainder of 2002 the Company granted a further 135,000 incentive
stock options at prices ranging from $5.50 per share to $8.50 per share subject
to immediate vesting. The fair value of these options at the date of grant of
$618,400 was estimated using the Black-Scholes option pricing model with an
expected life of three years, a risk-free interest rate of 4% and an expected
volatility of 229%. During 2002 the $618,400 was recorded as consulting fees in
connection with these options. During the period, the exercise price of these
options was reduced to $1.75 per share and as a result, these options are
subject to variable accounting in accordance with the provisions of the
Financial Accounting Standards Board Interpretation No.44, Accounting for
Certain Transactions Involving Stock Compensation - An Interpretation of APB
Opinion No. 25 ("FIN 44"). As at June 30, 2003, compensation expense of $33,750
has been recorded in connection with these options to reflect an increase in the
quoted market price of these options from $1.75 per share to $2.00 per share.
During the period ended June 30, 2003 the Company granted 300,000 stock options
to a consultant at a price of $1.00 per share subject to immediate vesting. The
fair value of these options at the date of grant of $504,000 was estimated using
the Black-Scholes option pricing model with an expected life of three years, a
risk-free interest rate of 3% and an expected volatility of 219%. During the
period the $504,000 was recorded as a consulting fee.
The Company's stock option activity, as restated to reflect the modification of
the exercise prices as described above, is as follows:
Weighted Average
Number of Weighted Average Remaining
options Exercise Price Contractual Life
___________________________________________________________
Balance, December 31, 2001 - $ - -
Granted prior to reverse acquisition 1,000,000 0.50
Granted in connection with reverse acquisition 2,135,000 1.00
Granted subsequent to reverse acquisition 135,000 1.75
Exercised during 2002 (102,000) 0.50
___________________________________________________________
Balance, December 31, 2002 3,168,000 0.89 2.33 years
Granted during the period 300,000 1.00
Forfeited during the period (50,000) 1.00
Exercised during the period (923,000) 0.51
___________________________________________________________
Balance, June 30, 2003 2,495,000 $ 1.04 2.33 years
===========================================================
GENEMAX CORP.
(A DEVELOPMENT STAGE COMPANY)
NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 2003
________________________________________________________________________________
(UNAUDITED)
NOTE 7 - CAPITAL STOCK (CONT'D)
________________________________________________________________________________
SHARE PURCHASE WARRANTS
In connection with the reverse acquisition of GPI, the Company assumed 744,494
share purchase warrants previously outstanding in GPI. In accordance with
accounting principles applicable to accounting for business combinations, the
fair value of the share purchase warrants assumed in connection with a business
combination is included in the determination of the purchase price. The fair
value of these share purchase warrants as at the date of the reverse acquisition
of $620,600 was estimated using the Black-Scholes option pricing model with an
expected life of 2.95 years, a risk-free interest rate of 4% and an expected
volatility of 236%.
The Company's share purchase warrant activity is as follows:
Weighted Average
Number of Weighted Average Remaining
warrants Exercise Price Contractual Life
____________________________________________________________
Balance, December 31, 2001 - $ - -
GPI warrants assumed 744,494 1.16
Issued during 2002 212,700 5.00
Exercised 2002 - -
Expired 2002 (110,334) 2.50
____________________________________________________________
Balance, December 31, 2002 846,860 1.95 2.71 years
Issued during the period 21,500 7.50
____________________________________________________________
Balance, June 30, 2003 868,360 $ 2.09 2.18 years
============================================================
NOTE 8 - INCOME TAXES
________________________________________________________________________________
There were no temporary differences between GPI's tax and financial bases that
result in deferred tax assets, except for the Company's net operating loss
carryforwards amounting to approximately $4,930,000 at June 30, 2003 which may
be available to reduce future year's taxable income. These carryforwards will
expire, if not utilized, commencing in 2008. Management believes that the
realization of the benefits from these deferred tax assets appears uncertain due
to the Company's limited operating history and continuing losses. Accordingly a
full, deferred tax asset valuation allowance has been provided and no deferred
tax asset benefit has been recorded.
Statements made in this Form 10-QSB that are not historical or current
facts are "forward-looking statements" made pursuant to the safe harbor
provisions of Section 27A of the Securities Act of 1933 (the "Act") and Section
21E of the Securities Exchange Act of 1934. These statements often can be
identified by the use of terms such as "may," "will," "expect," "believe,"
"anticipate," "estimate," "approximate" or "continue," or the negative thereof.
The Company intends that such forward-looking statements be subject to the safe
harbors for such statements. The Company wishes to caution readers not to place
undue reliance on any such forward-looking statements, which speak only as of
the date made. Any forward-looking statements represent management's best
judgment as to what may occur in the future. However, forward-looking statements
are subject to risks, uncertainties and important factors beyond the control of
the Company that could cause actual results and events to differ materially from
historical results of operations and events and those presently anticipated or
projected. The Company disclaims any obligation subsequently to revise any
forward-looking statements to reflect events or circumstances after the date of
such statement or to reflect the occurrence of anticipated or unanticipated
events.
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND PLAN OF
OPERATION
GENERAL
GeneMax Corp., a Nevada corporation (the "Company"), is a product-focused
biotechnology company specializing in the application of the latest discoveries
in cellular immunology and cancer biology to the development of proprietary
therapeutics aimed at the treatment and eradication of cancer and therapies for
infectious diseases, autoimmune disorders and transplant tissue rejection. The
Company's operating subsidiaries are GeneMax Pharmaceuticals Inc., a Delaware
corporation ("GeneMax Pharmaceuticals"), and the subsidiary of GeneMax
Pharmaceuticals named GeneMax Pharmaceuticals Canada Inc., which is a
corporation organized under the laws of British Columbia. The Company currently
trades on the OTC Bulletin Board under the symbol "GMXX". The Company is also
listed for trading on the Frankfurt Stock Exchange under the symbol "GX1".
PRIOR BUSINESS OPERATIONS
SHARE EXCHANGE AGREEMENT
During fiscal year ended December 31, 2002, the Company consummated and
finalized the acquisition of GeneMax Pharmaceuticals Inc., a Delaware
corporation ("GeneMax Pharmaceuticals"). On May 9, 2002 and effective July 15,
2002, Eduverse.com (now known as GeneMax Corp.), GeneMax Pharmaceuticals, the
shareholders of GeneMax Pharmaceuticals (the "GeneMax Shareholders"), and
Investor Communications International, Inc., a Washington corporation ("ICI")
entered into a share exchange agreement (the "Share Exchange Agreement"). In
accordance with the terms of the Share Exchange Agreement and the securities
laws of Canada, a Directors' Circular dated July 15, 2002 (the "Directors'
Circular") was distributed to certain management, insiders and directors of
GeneMax Pharmaceuticals and other Canadian shareholders (the "Canadian GeneMax
Shareholders").
Pursuant to the terms of the Share Exchange Agreement, the Directors'
Circular and related settlements, the Company acquired from the GeneMax
Shareholders and the Canadian GeneMax Shareholders one hundred percent (100%) of
the issued and outstanding shares of common stock of GeneMax Pharmaceuticals and
its subsidiary interest. In accordance with the terms of the Share Exchange
Agreement, the Directors' Circular and related settlement agreements, the
Company issued shares of its restricted common stock as follows: (i)
approximately 6,571,304 shares of restricted common stock to the GeneMax
Shareholders in proportion to their respective holdings in GeneMax
Pharmaceuticals; (ii) approximately 4,479,001 shares of restricted common stock
to the Canadian GeneMax Shareholders pursuant to the terms of the Directors'
Circular; (iii) 181,660 shares of restricted common stock to certain creditors
of GeneMax Pharmaceuticals at $0.75 per share for settlement of an aggregate
debt in the amount of $136,245; (iv) 188,154 shares of its restricted common
stock to certain creditors of GeneMax Pharmaceuticals at $1.00 per share for
settlement of an aggregate debt in the amount of $188,154; and (v) 200,000
shares of restricted common stock to a third party.
The Company issued an aggregate of 11,620,119 shares of its restricted
common stock under the Share Exchange Agreement and Directors' Circular. Certain
warrant instruments were issued in accordance with the terms and provisions of
warrant agreements pursuant to which the holder thereof has the right to convert
such warrant into shares of common stock on a one-to-one basis at either the
rate of $2.50 per share, $0.75 per share or $1.00 per share. Pursuant to the
Share Exchange Agreement, Directors' Circular and related settlement agreements,
there were an aggregate of 744,494 warrant instruments issued, of which 110,334
warrants were issued convertible into 110,334 shares of common stock at the rate
of $2.50 per share expiring on September 1, 2002. The 110,334 warrants were not
converted by the holders thereof into shares of common stock and expired on
their terms. Thus, as of the date of this Quarterly Report, there are an
aggregate of 634,160 warrant instruments issued comprised of the following: (i)
277,500 warrants issued and outstanding which may be converted into 277,500
shares of common stock at the rate of $1.00 per share expiring December 1, 2005;
(ii) 175,000 warrants issued and outstanding which may be converted into 175,000
shares of common stock at the rate of $1.00 per share expiring May 1, 2006; and
(iii) 181,660 warrants issued and outstanding which may be converted into
181,660 shares of common stock at the rate of $0.75 per share expiring May 1,
2006.
VOLUNTARY POOLING AGREEMENT
The Company and GeneMax Pharmaceuticals desired to provide for and maintain
an orderly trading market and stable price for the Company's shares of Common
Stock. Therefore, the Company, certain shareholders of GeneMax Pharmaceuticals
and of the Company, and Global Securities Transfer Inc., the Company's transfer
agent ("Global Securities"), entered into a voluntary pooling agreement dated
May 9, 2002 and effective July 15, 2002 (the "Pooling Agreement"). Pursuant to
the terms and provisions of the Pooling Agreement, certain shareholders of
GeneMax Pharmaceuticals and certain shareholders of the Company (the "Pooled
Shareholders") representing up to an aggregate of 9,166,980 shares of common
stock, respectively (the "Pooled Shares"), generally agreed that the Pooled
Shares will be subject to a contractual restrictive holding period. The Pooled
Shareholders further agreed that that the Pooled Shares may not be traded and
will become available for trading and released and sold in the following manner:
(i) an initial ten percent (10%) of the Pooled Shares will be released to the
Pooled Shareholders on the date which is one calendar year from the closing date
of the Share Exchange Agreement (the "First Release Date"); and (ii) a further
ten percent (10%) will be released to the Pooled Shareholders on each of the
dates which are every three (3) calendar months from the First Release Date in
accordance with each Pooled Shareholder's respective shareholdings. As of the
date of this Quarterly Report, the First Release Date has been extended a
further 12 months pursuant to approval by the Pooling Committee authorized by
the Board of Directors as contemplated under the terms and provisions of the
Pooling Agreement.
SECURED AND CONVERTIBLE LOAN AGREEMENT
As a condition to entering into and in accordance with the Share Purchase
Agreement, the Company and ICI agreed to advance to GeneMax Pharmaceuticals the
aggregate principal sum of not less than $250,000 within five (5) business days
of ICI raising an aggregate of $700,000. As a result of the acquisition, the
Loan became an intercompany account between the Company, as parent, and GeneMax
Pharmaceuticals, as subsidiary.
CURRENT BUSINESS OPERATIONS
The Company is a product-focused biotechnology company specializing in the
application of the latest discoveries in cellular immunology and cancer biology
to the development of proprietary therapeutics aimed at the treatment and
eradication of cancer and therapies for infectious diseases, autoimmune
disorders and transplant tissue rejection. The Company's technologies are based
on an understanding of the function of a protein "pump" within cells that is
essential in the processing of tumor antigens, known as Transporters associated
with Antigen Processing ("TAP").
The Company's strategic vision is to be a product-driven biotechnology
company, focusing primarily on use of its patented TAP technology to restore the
TAP function within cancerous cells, thus making them immunogenic. As a result,
the MHC Class I Proteins, which is defined as when cancers are not able to cause
an immune response because they no longer express key immune proteins on their
cell surface (known as "MHC Class I Proteins"), can signal the immune system to
attack the cancer. The Company intends to develop the TAP technology as a
therapeutic cancer vaccine that will restore the normal immune recognition.
Management believes that its cancer vaccine is the only therapeutic approach
that addresses this problem of "non-immunogenicity" of cancer. Management
believes that this therapy will have a strong competitive advantage over other
cancer therapies, since restoring the TAP protein will direct the immune system
to specifically target the cancerous cells without damaging healthy tissue.
PRODUCTS
TAP CANCER VACCINE
The Company has developed a patented therapeutic cancer vaccine to restore
the TAP protein (the "TAP Cancer Vaccine"). The TAP Cancer Vaccine is targeted
at those cancers that are deficient in the TAP protein, which include commonly
occurring breast cancer, prostate cancer, lung cancer, liver cancer, melanoma,
renal cancer and colorectal cancer.
The TAP Cancer Vaccine would deliver the TAP protein and genetic
information, thus "turning on" the defective TAP signaling system within the
cancer cells. These cancer cells would then transport cancer antigen proteins to
the cell surface using the individual's specific MHC Class I proteins. As a
result, the immune response would be targeted to the entire repertoire of cancer
antigen proteins produced by the cancer cell, rather than just to the single
cancer antigen (as delivered by usage of current cancer vaccines). The TAP
Cancer Vaccine would allow the immune response to respond to the cancer even if
the TAP protein and genetic information is only delivered to a small portion of
the cancer cells. In addition, the TAP Cancer Vaccine would generate a strong
immune response to any TAP-deficient cancer, regardless of the patient's
individual genetic variability either in the MHC Class I proteins or in the
cancer-specific proteins.
TAP CANCER VACCINE DEVELOPMENT PROGRAM. The Company is currently developing
the TAP Cancer Vaccine at the University of British Columbia Biomedical Research
Centre under a collaborative research agreement.
COLLABORATIVE RESEARCH AGREEMENT. During May 2000, GeneMax Pharmaceuticals
and the BRC Biotechnology Laboratory at the University of British Columbia
("BRC") entered into a contract research agreement (the "Collaborative Research
Agreement"), to carry out further development of the TAP technologies as a
cancer vaccine and other commercial products and to provide GeneMax
Pharmaceuticals with the option to acquire the rights to commercialize any
additional technologies developed with the Collaborative Research Agreement. In
accordance with the terms of the Collaborative Research Agreement: (i) the
Company provides funding pursuant to certain commitments for three PHD
scientists, as well as support technicians and students; (ii) BRC provides the
Company with access to the laboratories and equipment at the BRC, as well as
other facilities of the University of British Columbia; and (iii) Dr. Wilfred
Jefferies, the inventor of the TAP technologies and the Chief Scientific Officer
and a director of the Company, will provide supervision of all scientific
activity.
Pursuant to a series of amendments to the Collaborative Research Agreement,
the funding commitment was increased to an aggregate of $2,973,049 Canadian
Dollars, of which $991,515 was to be paid during fiscal year ended December 31,
2002, $1,135,801 to be paid during fiscal year ended December 31, 2003, and
$471,518 to be paid during fiscal year ended December 31, 2004. As of June 30,
2003, an aggregate of $433,677 Canadian Dollars is payable by GeneMax
Pharmaceuticals in connection with the Collaborative Research Agreement.
Moreover, in accordance with the terms of the Collaborative Research Agreement,
GeneMax Pharmaceuticals has purchased certain laboratory equipment in connection
with the ongoing research.
As of the date of this Quarterly Report, the research under the
Collaborative Research Agreement will continue in the future to support the
commercial development of the TAP Cancer Vaccine and to develop enhanced vaccine
products and other therapeutics based on the TAP technology.
LICENSE AGREEMENT. During March 2000, GeneMax Pharmaceuticals and the
University of British Columbia ("UBC") entered into an exclusive world-wide
license agreement (the "License Agreement"). Pursuant to the terms of the
License Agreement, UBC granted to GeneMax Pharmaceuticals exclusive licensing
rights to certain patented and unpatented cancer immuno-therapy technologies
originally invented and developed by Dr. Jefferies and the scientific team at
UBC including the: (i) cell-based peptide transfer assay (the "Peptide Transfer
Assay"), and (ii) cancer immuno-therapy based on restoration of antigen
presentation through transporters associated with antigen-processing
technologies, the basis for the Company's lead product which is the TAP Cancer
Vaccine. GeneMax Pharmaceuticals obtained the exclusive licensing rights to this
technology for the consideration of $78,743 and issuance to UBC of equity, with
no royalty components or provisions. Pursuant to further terms of the License
Agreement: (i) the License Agreement will terminate after the latter of fifteen
years or the expiration of the last patent obtained relating to the licensed
technology; (ii) GeneMax Pharmaceuticals will bear the cost of obtaining any
patents; and (iii) the technology remains the property of UBC, however, it may
be utilized and improved by GeneMax Pharmaceuticals. The Company expects the
approval of multiple further patents.
NETWORK AFFILIATE AGREEMENT. On January 1, 2001, GeneMax Pharmaceuticals,
UBC and the Canadian Network for Vaccines and Immunotherapeutics of Cancer and
Chronic Viral Diseases ("CANVAC") entered into a one-year network affiliate
agreement (the "Network Affiliate Agreement"). Pursuant to the terms of the
Network Affiliate Agreement, CANVAC would provide an $85,000 Canadian Dollars
research grant to UBC to further fund research activities upon GeneMax
Pharmaceuticals contributing $117,300 Canadian Dollars towards the UBC research.
During fiscal year 2001, all amounts required under the Network Affiliate
Agreement were paid by GeneMax Pharmaceuticals to UBC. As of the date of this
Quarterly Report, GeneMax Pharmaceuticals and CANVAC are no longer negotiating
an amendment to the Network Affiliate Agreement regarding continuation of
funding the research activities conducted at UBC. As of the date of this
Quarterly Report, the balance due and owing to UBC by GeneMax Pharmaceuticals is
$38,709 (Canadian Dollars).
TAP CANCER VACCINE TESTING PROGRAM. Management of the Company believes that
the key milestone of efficacy in animal models of cancer has been attained and
that other scientific research teams have independently validated the
experimental data from these animal studies. The proof of principle for TAP as a
cancer vaccine was established in research conducted the last ten years in the
laboratory at BRC by Dr. Wilfred Jefferies. The initial studies were conducted
using a small-cell lung cancer cell line that was derived from an aggressive,
metastatic cancer. These cells have multiple defects in the "antigen
presentation pathway" in that they are not detected by the immune system. When
the TAP protein was introduced into these cells, antigen presentation was
restored. In addition, a series of animal studies have demonstrated the ability
of TAP to restore an immune response. This study was published in Nature
Biotechnology (Vol. 18, pp. 515-520, May 2000). The TAP Technology was further
validated in melanoma.
PRE-CLINICAL TESTING. As of the date of this Quarterly Report, the TAP
Cancer Vaccine is undergoing formal pre-clinical testing, which includes: (i)
evaluation of several strains of vaccinia and adenovirus vectors for their
respective ability to deliver and express the TAP protein and genetic
information in tumors; (ii) selection and licensing of the vector and
identification and contracting with a good manufacturing practice ("GMP")
manufacturer for subsequent production of the TAP Cancer Vaccine; and (iii)
performance and completion of toxicology studies using the TAP Cancer Vaccine on
at least two animal species to confirm its non-toxicity.
Upon completion of the formal pre-clinical testing, the Company intends to
compile and summarize the data and submit it to two governmental agencies, the
U.S. Federal Drug Administration ("FDA") and the Canadian Health Canada ("HC"),
in the form of an investigational new drug application (the "IND"). The IND will
include data on the vaccine production, animal studies and toxicology studies,
as well as the proposed protocal for the Phase I human clinical trials.
PHASE I HUMAN CLINICAL TRIALS. Management of the Company believes that the
Phase I human clinical trials will be commenced approximately second quarter of
2004, subject to financing, and will be conducted at the British Columbia Cancer
Agency in Vancouver, British Columbia. As of the date of this Quarterly Report,
the Company has presented information on the TAP Cancer Vaccine to members of
the Department of Advanced Therapeutics. The Phase I trials will generally be
designed to provide data on the safety of the TAP Cancer Vaccine when used by
humans.
PEPTIDE TRANSFER ASSAY
The Company is also currently developing potential products that may
interrupt the chain of events involved in certain autoimmune diseases. As of the
date of this Quarterly Report, the Company is developing a peptide transfer
assay, which is a cell-based assay designed to evaluate compounds and drugs for
their ability to stimulate or suppress the immune response (the "Peptide
Transfer Assay"). The Peptide Transfer Assay's application will be to identify
compounds effective in the treatment of cancer, infectious diseases, and
autoimmune diseases. Autoimmune diseases include psoriasis, rheumatoid
arthritis, multiple sclerosis, myasthenia gravis and diabetes. T cells and
antibodies in the body's immune system normally identify and destroy foreign
substances and cancerous cells. Autoimmune diseases are generally caused by the
abnormal destruction of healthy body tissues when T cells and antibodies react
against normal tissue.
Management of the Company believes that the Peptide Transfer Assay is a
novel and sophisticated cell-based assay. Management of the Company expects that
the Peptide Transfer Assay will be of significant interest to pharmaceutical
companies, companies with natural product libraries, anti-sense or gene
libraries or proprietary rights to chemical compounds (e.g. combinatorial
chemistry companies). As of the date of this Quarterly Report, management of the
Company believes that the Peptide Transfer Assay is ready for development for
high-throughput screening and partnering.
INTELLECTUAL PROPERTY, PATENTS AND TRADEMARKS
Patents and other proprietary rights are vital to the business operations
of the Company. The Company's policy is to seek appropriate patent protection
both in the United States and abroad for its proprietary technologies and
products. Pursuant to the License Agreement, the Company has acquired the
exclusive world-wide license to a portfolio of intellectual property as follows:
METHOD OF ENHANCING EXPRESSION OF MHC CLASS I MOLECULES BEARING ENDOGENOUS
PEPTIDES
On March 26, 2002, the United States Patent and Trademark Office issued a
patent for the use of "TAP-1 (transporters associated with antigen processing)
as an immunotherapy against all cancers ("US Patent No. 6,361,770"). The patent
is titled "Method of Enhancing Expression of MHC Class I Molecules Bearing
Endogenous Peptides" and provides comprehensive protection and coverage to both
in vivo and ex vivo applications of TAP-1 as a therapeutic against all cancers
with a variety of delivery mechanisms. The inventors were Dr. Wilfred Jefferies,
Dr. Reinhard Gabathuler, Dr. Gerassimos Kolaitis and Dr. Gregor S.D. Reid, who
collectively assigned the patent to UBC. During the lengthy application process,
many proofs of the application were required by the U.S. Patent and Trademark
Office for a patent of such relevance and applicability to all cancers to be
approved, and included proofs in multiple forms of cancer tumors including small
cell lung carcinoma and melanoma cancer. Management of the Company considers
issuance of this patent as a major product development milestone for the
Company.
As of the date of this Quarterly Report, the Company has pending
applications filed for patent protection in France, United Kingdom, Germany,
Switzerland and Japan.
METHOD OF IDENTIFYING MHC CLASS I RESTRICTED ANTIGENS ENDOGENOUSLY
PROCESSED BY A SECRETORY PATHWAY
On August 11, 1998, the U.S. Patent and Trademark Office issued to UBC a
patent for the use of bioengineered cell lines to measure the output of the MHC
Class I restricted antigen presentation pathway as a way to screen for
immunomodulating drugs ("US Patent No. 5,792,604"). The patent is titled "Method
of Identifying MHC Class I Restricted Antigens Endogenously Processed by a
Secretory Pathway." This patent covers the assay which can identify compounds
capable of modulating the immune system. The inventors were Dr. Wilfred
Jefferies, Dr. Reinhard Gabathuler, Dr. Gerassimos Kolaitis and Dr. Gregor S.D.
Reid, who collectively assigned the patent to UBC.
As of the date of this Quarterly Report, the Company has pending
applications filed for patent protection in Canada, Japan and Europe.
METHOD OF ENHANCING EXPRESSION OF MHC CLASS I MOLECULES BEARING ENDOGENOUS
PEPTIDES
UBC filed a patent application with the U.S. Patent and Trademark Office
for patent protection of extension of the TAP-1 for use in viral vaccines as a
method for increasing immune responses. As of the date of this Quarterly Report,
UBC has not received an order granting a patent.
The Company intends to continue to work with UBC to file additional patent
applications with respect to any novel aspects of its technology to protect its
intellectual property. The Company has not conducted in-depth validity and
infringement studies on the patents and patent applications that the Company has
in-licensed, and it is possible that these patents or patent applications may be
challenged or may not provide protection.
The patent positions of biotechnology and pharmaceutical companies are
generally uncertain and involve complex legal and factual issues. No assurance
can be given that any patent issued to or licensed by the Company will provide
protection that has commercial significance. The Company cannot assure that: (i)
the patents will afford protection against competitors with similar compounds or
technologies; (ii) the patent applications pending will be issued; (iii) other
companies will not obtain patents claiming aspects or technologies similar to
those covered by the issued patents; (iv) the patents of other companies will
not have an adverse effect on the Company's ability to do business; or (v) the
patents issued to or licensed by the Company will not be infringed, challenged,
invalidated or circumvented.
Moreover, management of the Company believes that obtaining foreign patents
may, in some cases, be more difficult than obtaining domestic patents because of
differences in patent laws. The Company also recognizes that the patent
protection may generally be stronger in the United States and Canada than
abroad. Conversely, the protection provided by foreign patents may be weaker
than that provided by domestic patents.
RESULTS OF OPERATION
The Company's financial statements have been prepared which incorporate
financial data and figures of GeneMax Pharmaceuticals. Thus, the comparative
results are those of GeneMax Pharmaceuticals prior to the acquisition and are
not the financial results of the Company, and the current period comparative
results include the financial data and figures of the Company subsequent to the
acquisition of GeneMax Pharmaceuticals. The following discussions of the results
of operations and financial position of the Company should be read in
conjunction with the financial statements and notes pertaining to them that
appear elsewhere in this Form 10-QSB.
SIX-MONTH PERIOD ENDED JUNE 30, 2003 COMPARED TO SIX-MONTH PERIOD ENDED JUNE 30,
2002
The Company's net losses during the six-month period ended June 30, 2003
were approximately ($2,155,039) compared to a net loss of approximately
($594,668) during the six-month period ended June 30, 2002 (an increase of
$1,560,371).
Net revenues during the six-month periods ended June 30, 2003 and 2002 were
$-0-. The lack of revenues during the six-month periods ended June 30, 2003 and
2002 resulted from the consummation of the acquisition of GeneMax
Pharmaceuticals and the resulting emphasis on the research and development of
the TAP Technologies. Interest income of $29 was recorded for the six-month
period ended June 30, 2002.
During the six-month period ended June 30, 2003, the Company recorded
operating expenses of $2,155,039 compared to $594,697 of operating expenses
recorded during the six-month period ended June 30, 2002 (an increase of
$1,560,342). The operating expenses incurred during the six-month period ended
June 30, 2003 consisted primarily of the following: (i) office and general
expenses of approximately $610,346 compared to $41,803 incurred during the
six-month period ended June 30, 2002; (ii) research and development of
approximately $568,647 compared to $362,641 incurred during the six-month period
ended June 30, 2002; (iii) $561,500 recorded as consulting fees relating to the
grant of stock options compared to $-0- recorded as consulting fees relating to
grant of stock options during the six-month period ended June 30, 2002; (iv)
professional fees of approximately $154,198 compared to $72,249 incurred during
the six-month period ended June 30, 2002; (v) management fees of approximately
$111,690 compared to $60,322 incurred during the six-month period ended June 30,
2002; (vi) consulting fees of approximately $84,718 compared to $35,500 incurred
during the six-month period ended June 30, 2002; (vii) travel expenses of
approximately $42,527 compared to $1,821 incurred during the six-month period
ended June 30, 2002; and (viii) depreciation expenses of approximately $21,413
compared to $20,361 incurred during the six-month period ended June 30, 2002.
The overall increase in operating expenses, including the increase in office and
general expenses and research and development expenses, is due primarily to the
increased scale and scope of overall corporate activity pertaining to the
acquisition of GeneMax Pharmaceuticals and the ongoing research and development
relating to the TAP technology and the TAP Cancer Vaccine.
Of the $2,155,039 incurred as operating expenses, an aggregate of $208,874
was incurred payable to certain directors and/or private companies controlled by
those directors of the Company pursuant to consulting, management and research
and development agreements as described in the following paragraphs.
CONSULTING SERVICES AGREEMENT. The Company and Investor Communications
International Inc. ("ICI") entered into a consulting services agreement dated
August 12, 2002 (the "Consulting Services Agreement"). Pursuant to the terms and
provisions of the Consulting Services Agreement: (i) ICI shall provide to the
Company such finance and managerial services as may be determined by the Board
of Directors, from time to time, and in its sole and absolute discretion, in
order to develop the various business interests of the Company in the drug
discovery and development industry, involving the patented drug discovery assay
for immunomodulatory compounds and the pipeline aimed at treatment of cancer,
infectious diseases, autoimmune disorders and transplant tissue rejection; and
(ii) the Company shall pay ICI a monthly fee not to exceed $10,000 in accordance
with the services performed.
During the six-month period ended June 30, 2003, an aggregate of $60,000 in
fees was incurred to ICI for services rendered to the Company under the
Consulting Services Agreement on a month-to-month basis, as needed. In addition,
ICI incurred expenses on behalf of the Company during the period totaling
$601,412. Based upon $2,154, which remained due and owing to ICI at December 31,
2002, this resulted in $663,566 due and owing to ICI. During the six-month
period ended June 30, 2003, the Company paid ICI $402,323. As of June 30, 2003,
an aggregate amount of $261,243 remains due and owing to ICI by the Company
relating to fees, cash advances and interest.
Mr. Grant Atkins, a director of the Company, is employed by ICI and is part
of the management team provided by ICI to the Company, and derives remuneration
from ICI for such services rendered to the Company. During the six-month period
ended June 30, 2003, Mr. Atkins received $19,625 from ICI as compensation for
services rendered to the Company.
GENEMAX PHARMACEUTICALS CONSULTING AGREEMENT. GeneMax Pharmaceuticals and
442668 B.C. Ltd. ("442668"), a corporation whose president and member of the
board of directors is Dr. Wilfred Jefferies, a director and the Chief Scientific
Officer of the Company, entered into a consulting services agreement dated
February 1, 2000 (the "GeneMax Pharmaceuticals Consulting Agreement"). Pursuant
to the terms and provisions of the GeneMax Pharmaceuticals Consulting Agreement:
(i) Dr. Jefferies agreed to provide technical, research and technology
development services to GeneMax Pharmaceuticals for a period of five years; and
(ii) Dr. Jefferies shall be paid a monthly fee of $10,000 Canadian Dollars and
reimbursement of expenses.
During the six-month period ended June 30, 2003, an aggregate of $44,245 in
fees was incurred to 442668 for services rendered by Dr. Jefferies to the
Company under the GeneMax Pharmaceuticals Consulting Agreement. During the
six-month period ended June 30, 2003, the Company paid $36,332 to 442668. As of
June 30, 2003, an aggregate amount of $7,913 remains due and owing to 442668 by
the Company.
During the six-month period ended June 30, 2003, Dr. Jefferies received
$44,245 through 442668 as compensation for services rendered to the Company
under the GeneMax Pharmaceuticals Consulting Agreement.
GENEMAX PHARMACEUTICALS MANAGEMENT AGREEMENT. GeneMax Pharmaceuticals and
Ronald L. Handford, the President/Chief Executive Officer and a director of the
Company ("Handford"), entered into a management services agreement dated August
1, 1999 (the "GeneMax Pharmaceuticals Management Agreement"). Pursuant to the
terms and provisions of the GeneMax Pharmaceuticals Management Agreement: (i)
Handford agreed to provide general managerial services to GeneMax
Pharmaceuticals for a period of five years; and (ii) Handford shall be paid a
monthly fee of $11,000 U.S. Dollars and reimbursement of expenses. Effective May
1, 2002, GeneMax Pharmaceuticals and Handford agreed to reduce the monthly fee
to $12,500 Canadian Dollars until the earlier of the Company reaching a senior
board listing or commencement of clinical trials, at which time the fee will be
reviewed in accordance with market norms.
During the six-month period ended June 30, 2003, an aggregate of $51,690 in
fees was incurred to Handford for services rendered by Handford to the Company
under the GeneMax Pharmaceuticals Management Agreement. Based upon $16,332,
which was due and owing to Handford at December 31, 2002, this resulted in
$68,022 due and owing Handford. During the six-month period ended June 30, 2003,
the Company paid Handford $42,446. As of June 30, 2003, an aggregate amount of
$25,576 remains due and owing to Handford by the Company.
GENEMAX PHARMACEUTICALS SERVICES AGREEMENT. GeneMax Pharmaceuticals and
Alan Lindsay and Associates Ltd. ("AL&A"), a corporation whose sole officer,
director and shareholder is Alan Lindsay, a prior director of the Company,
entered into a services agreement dated May 31, 2002 (the "GeneMax
Pharmaceuticals Services Agreement"). Pursuant to the terms and provisions of
the GeneMax Pharmaceuticals Services Agreement, Mr. Lindsay agreed to provide
general consulting services to GeneMax Pharmaceuticals on a month-to-month
basis. Pursuant to further terms and provisions of the GeneMax Pharmaceuticals
Services Agreement, AL&A was to be paid a monthly fee of $2,500 U.S. Dollars and
reimbursement of expenses.
During the six-month period ended June 30, 2003, an aggregate of $10,000 in
fees was incurred to AL&A for services rendered to the Company under the GeneMax
Pharmaceuticals Services Agreement. Based upon $12,500, which remained due and
owing to AL&A at December 31, 2002, this resulted in $22,500 due and owing AL&A.
During the six-month period ended June 30, 2003, the Company paid AL&A $10,000.
As of June 30, 2003, an aggregate amount of $12,500 remains due and owing to
AL&A.
During the six-month period ended June 30, 2003, Mr. Lindsay received an
aggregate of $10,000 through AL&A as compensation for services rendered to the
Company under the GeneMax Pharmaceuticals Services Agreement.
As of May 7, 2003, Mr. Lindsay tendered his resignation as a member of the
board of directors of the Company. Therefore, as of May 7, 2003, the GeneMax
Pharmaceuticals Services Agreement was terminated.
DAVIDSON AGREEMENT. GeneMax Pharmaceuticals and James D. Davidson
("Davidson"), previously the Chief Financial Officer and a director of the
Company, entered into a verbal month-to-month agreement (the "Davidson
Agreement"). Pursuant to the terms of the Davidson Agreement: (i) Davidson
agreed to perform such duties and services as required commensurate with his
position as the Chief Financial Officer of the Company and such other duties
commensurate with this position as a director on the Board of Directors; (ii)
Davidson was to be paid a monthly fee of $2,000 and reimbursement of expenses.
Effective July 15, 2002, GeneMax Pharmaceuticals agreed to increase the monthly
fee to $5,000 upon commencement of Davidson's duties associated with his
position as Chief Financial Officer and a director of the Company after the
acquisition of GeneMax Pharmaceuticals.
During the six-month period ended June 30, 2003, an aggregate of $20,000 in
fees was incurred to Davidson for services rendered by Davidson to the Company
under the Davidson Agreement. During the six-month period ended June 30, 2003,
the Company paid Davidson $20,000. As of June 30, 2003, an aggregate amount of
$-0- remains due and owing to Davidson by the Company.
As of April 16, 2003, Mr. Davidson tendered his resignation as the Chief
Financial Officer and a member of the board of directors of the Company.
Therefore, as of April 16, 2003, the Davidson Agreement was terminated.
As discussed above, the increase in net loss during the six-month period
ended June 30, 2003 as compared to the six-month period ended June 30, 2002 is
attributable primarily to the increased scale and scope of overall corporate
activity pertaining to the ongoing research and development relating to the TAP
technology and the TAP Cancer Vaccine. The Company's net loss during the
six-month period ended June 30, 2003 was approximately ($2,155,039) or ($0.13)
per common share compared to a net loss of approximately ($594,668) or ($0.05)
per common share during the six-month period ended June 30, 2002. The weighted
average of common shares outstanding were 16,535,591 for the six-month period
ended June 30, 2003 compared to 11,431,965 for the six-month period ended June
30, 2002.
THREE-MONTH PERIOD ENDED JUNE 30, 2003 COMPARED TO THREE-MONTH PERIOD ENDED JUNE
30, 2002
The Company's net losses during the three-month period ended June 30, 2003
were approximately ($1,280,391) compared to a net loss of approximately
($361,987) during the three-month period ended June 30, 2002 (an increase of
$918,404).
Net revenues during the three-month periods ended June 30, 2003 and 2002
were $-0-. Interest income of $29 was recorded for the three-month period ended
June 30, 2002.
During the three-month period ended June 30, 2003, the Company recorded
operating expenses of $1,280,391 compared to $362,016 of operating expenses
recorded during the three-month period ended June 30, 2002 (an increase of
$918,375). The operating expenses incurred during the three-month period ended
June 30, 2003 consisted primarily of the following: (i) 549,625 recorded as
consulting fees relating to the grant of stock options compared to $-0- recorded
as consulting fees relating to grant of stock options during the three-month
period ended June 30, 2002; (ii) office and general expenses of approximately
$244,589 compared to $22,792 incurred during the three-month period ended June
30, 2002; (iii) research and development of approximately $293,871 compared to
$249,992 incurred during the three-month period ended June 30, 2002; (iv)
professional fees of approximately $68,444 compared to $45,213 incurred during
the three-month period ended June 30, 2002; (v) consulting fees of approximately
$28,718 compared to $6,014 incurred during the three-month period ended June 30,
2002; (vi) management fees of approximately $56,844 compared to $27,322 incurred
during the three-month period ended June 30, 2002; (vii) travel expenses of
approximately $27,569 compared to $503 incurred during the three-month period
ended June 30, 2002; and (viii) depreciation expenses of approximately $10,731
compared to $10,180 incurred during the three-month period ended June 30, 2002.
The overall increase in operating expenses, including the increase in office and
general expenses and research and development expenses, is due primarily to the
increased scale and scope of overall corporate activity pertaining to the
ongoing research and development relating to the TAP technology and the TAP
Cancer Vaccine.
As discussed above, the increase in net loss during the three-month period
ended June 30, 2003 as compared to the three-month period ended June 30, 2002 is
attributable primarily to the increased scale and scope of overall corporate
activity pertaining to the ongoing research and development relating to the TAP
technology and the TAP Cancer Vaccine. The Company's net loss during the
three-month period ended June 30, 2003 was approximately ($1,280,391) or ($0.08)
per common share compared to a net loss of approximately ($361,987) or ($0.03)
per common share during the three-month period ended June 30, 2002. The weighted
average of common shares outstanding were 16,813,123 for the three-month period
ended June 30, 2003 compared to 11,431,965 for the three-month period ended June
30, 2002.
LIQUIDITY AND CAPITAL RESOURCES
The Company's financial statements have been prepared assuming that it will
continue as a going concern and, accordingly, do not include adjustments
relating to the recoverability and realization of assets and classification of
liabilities that might be necessary should the Company be unable to continue in
operation.
SIX-MONTH PERIOD ENDED JUNE 30, 2003
As of June 30, 2003, the Company's current assets were $52,204 and its
current liabilities were $804,082, which resulted in a working capital deficit
of $751,878. As of June 30, 2003, the Company's total assets were $144,436
consisting of: (i) $52,204 in current assets comprised of $46,204 in cash and
$6,000 in prepaid expenses; and (ii) $92,232 in furniture and equipment (net of
depreciation). As of June 30, 2003, the Company's total liabilities of $804,082
consisted primarily of: (i) $492,927 in accounts payable and accrued
liabilities; and (ii) amounts due to related parties of $311,155 pertaining to
the managerial and consulting agreements discussed above.
As of June 30, 2003, the Company's stockholders' equity (capital
deficiency) decreased to ($659,646) from $484,028 at March 31, 2003.
The Company has not generated positive cash flows from operating
activities. For the six-month period ended June 30, 2003, net cash flows used in
operating activities was ($1,343,812) compared to ($473,827) of net cash flows
used in operating activities for the six-month period ended June 30, 2002 (an
increase of $869,985). The increase in cash flows used in operating activities
during the six-month period ended June 30, 2003 compared to the six-month period
ended June 30, 2002 resulted from: (i) a net loss of ($2,155,039) incurred
during the six-month period ended June 30, 2003 compared to a net loss of
($594,668) incurred during the six-month period ended June 30, 2002; (ii) an
increase in stock-based compensation to $561,500 during the six-month period
ended June 30, 2003 compared to $-0- during the six-month period ended June 30,
2002; and (iii) an increase in accounts payable to $228,314 during the six-month
period ended June 30, 2003 compared to $100,480 during the six-month period
ended June 30, 2002.
The Company's cash flows used in investing activities during the six-month
period ended June 30, 2003 was ($806) compared to cash flows from investing
activities of $250,000 during the six-month period ended June 30, 2002. The
change in cash flows used in investing activities during the six-month period
ended June 30, 2003 compared to cash flows from investing activities during the
six-month period ended June 30, 2002 resulted primarily from pre-reverse
acquisition advances from Eduverse.com in the amount of $250,000 recorded during
the six-month period ended June 30, 2002 compared to $-0- recorded during the
six-month period ended June 30, 2003.
Net cash flows from financing activities was $774,169 during the six-month
period ended June 30, 2003 compared to $346,388 in net cash flows from financing
activities during the six-month period ended June 30, 2002. The increase in net
cash flows from financing activities during the six-month period ended June 30,
2003 compared to the six-month period ended June 30, 2002 resulted primarily
from proceeds on sale and subscription of common stock in the amount of $494,000
compared to $170,500 during the six-month period ended June 30, 2002 and from
advances from related parties in the amount of $280,169 compared to $107,343
during the six-month period ended June 30, 2002.
OFF-BALANCE SHEET ARRANGEMENTS
As of the date of this Quarterly Report, the Company does not have any
off-balance sheet arrangements that have or are reasonably like to have a
current or future effect on the Company's financial condition, changes in
financial condition, revenues or expenses, results of operations, liquidity,
capital expenditures or capital resources that are material to investors. The
term "off-balance sheet arrangement" generally means any transaction, agreement
or other contractual arrangement to which an entity unconsolidated with the
Company is a party, under which the Company has (i) any obligation arising under
a guarantee contract, derivative instrument or variable interest; or (ii) a
retained or contingent interest in assets transferred to such entity or similar
arrangement that serves as credit, liquidity or market risk support for such
assets.
PLAN OF OPERATION
As of the date of this Quarterly Report, management of the Company
estimates that GeneMax Pharmaceuticals previously raised approximately
$2,000,000 in funding and the Company has raised $2,503,500 in funding since the
May 2002 announcement of the GeneMax Pharmaceuticals acquisition. Management of
the Company believes that an estimated $14,000,000 is required over the next
three years for payment of expenses associated with the balance of pre-clinical
development and commencement of Phase I-II clinical trials for the TAP Cancer
Vaccine and for corporate expenses and other expected development initiatives.
FUNDING
During the last quarter of fiscal year ended December 31, 2002, the Company
terminated an offering of 1,000,000 Units at $2.50 per Unit. Each Unit consists
of one share of restricted common stock of the Company (the "Share") and
one-half of one non-transferable share purchase warrant (the Warrant"), with
each whole Warrant convertible into one share of common stock at $5.00 per whole
Warrant. The Company sold 425,400 Units and received $1,063,500 in gross
proceeds.
Current management of the Company anticipates an increase in operating
expenses over the next three years to pay expenses associated with the
successful completion of the balance of pre-clinical development and
commencement of Phase I-II clinical trials for the TAP Technology and corporate
expenses. Pursuant to these operational requirements, the Company must raise
additional funds. The Company may finance these expenses with further issuance
of common stock of the Company. The Company believes that any anticipated
private placements of equity capital and debt financing, if successful, may be
adequate to fund the Company's operations over the next twelve months.
Thereafter, the Company expects it will need to raise additional capital to meet
long-term operating requirements. If the Company raises additional funds through
the issuance of equity or convertible debt securities other than to current
shareholders, the percentage ownership of its current shareholders would be
reduced, and such securities might have rights, preferences or privileges senior
to its common stock. Additional financing may not be available upon acceptable
terms, or at all. If adequate funds are not available or are not available on
acceptable terms, the Company may not be able to conduct its proposed business
operations successfully, which could significantly and materially restrict or
delay the Company's overall business operations.
Management of the Company estimates that as of the date of this Quarterly
Report, the Company has raised approximately $2,899,500 in funding, in addition
to funds raised privately by GeneMax Pharmaceuticals prior to the acquisition.
Management of the Company believes that an estimated $14,000,000 is required
over the next three years for payment of expenses associated with the balance of
pre-clinical development and commencement of Phase I-II clinical trials for the
TAP Cancer Vaccine. The Company must raise additional capital to execute its
business plan according to time schedules provided by management. Furthermore,
the Company has not generated sufficient cash flow in the past to fund its
operations and activities due primarily to the nature of lengthy product
development cycles that are normal to the biotech industry. Historically, the
Company has relied upon internally generated funds, funds from the sale of
shares of stock and loans from its shareholders and private investors to finance
its operations and growth. The Company's future success and viability are
dependent on the Company's ability to raise additional capital through further
private offerings of its stock or loans from private investors. There can be no
assurance, however, that the Company will be able to raise additional capital.
The Company's inability to successfully raise additional capital would have a
material and adverse affect upon the Company and its shareholders.
ITEM III. CONTROLS AND PROCEDURES
(a) The Company, under the supervision of the President, has conducted an
evaluation of the effectiveness of the design and operation of the Company's
disclosure controls and procedures within ninety (90) days of the filing date of
this Quarterly Report. Based upon the results of this evaluation, the Company
believes that they maintain proper procedures for gathering, analyzing and
disclosing all information in a timely fashion that is required to be disclosed
in its reports under the Securities Exchange Act of 1934, as amended. There have
been no significant changes in the Company's controls subsequent to the
evaluation date.
(b) There were no significant changes in the Company's internal control or
in other factors that could significantly affect the Company's internal controls
subsequent to the evaluation date.
PART II. OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
(a) On approximately May 9, 2003, the Company initiated litigation against
LOM Securities (Bermuda) Limited, LOM (Holdings) Limited, Brian Lines, and Black
Corporations 1-100 (the "LOM Defendants"), by filing a Complaint and Demand for
Jury in the United States District Court, State of Nevada, Case No.
CV-N-03-0246-HDM-VPC (the "LOM Complaint"). The claims made by the Company
against the LOM Defendants involve the alleged establishment, facilitation and
participation, directly or indirectly, in activities allowing the LOM Defendants
and others to establish and/or hold "short" positions in the Company's common
stock and causing at least 1,916,833 restricted shares of common stock of the
Company to be included in and reflected on investment account statements of
clients of the LOM Defendants which were not, in fact, on deposit in such client
accounts. The LOM Complaint further alleges that the LOM Defendant failed and
refused to take reasonable measure or care with regard to their trading,
clearing and/or transfer of shares of the Company and breached their respective
duties in contravention of the laws and rules and regulations of the Securities
Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended.
The claims against the LOM Defendants also specifically allege fraud and
misrepresentation, negligence, conversion, deceptive trade practice,
racketeering, interference with contracts and interference with prospective
economic advantages. The Company is seeking damages in excess of $10,000,000.
(b) On approximately September 4, 2002, the Company initiated litigation
against Global Securities Corporation and Union Securities Corporation (the
"B.C. Defendants") by filing a Writ of Summons and Statement of Claim in the
Supreme Court of British Columbia, Registry No. S024914 (the "British Columbia
Complaint"). The claims made by the Company against the B.C. Defendants in the
British Columbia Complaint involve the alleged illegal naked short selling of
the Company's shares of common stock conducted by the B.C. Defendants to
manipulate share price for profit and gain in violation of the provisions of the
Company's bylaws, the Investment Dealers Association of Canada, the National
Association of Securities Dealers, the Criminal Code of Canada, and the
Securities Exchange Act of 1934, as amended (the "Naked Short Sales"). The
claims against the B.C. Defendants specifically allege violation of fair-trading
practices, negligence and/or fraud and share price manipulation. The Company is
seeking damages from the B.C. Defendants resulting from the alleged actions of
the B.C. Defendants that include loss of investment opportunity, injury to
reputation, artificial issuance of shares that results in illegal devaluation of
the Company's securities, and other damages.
As of the date of this Quarterly Report, the B.C. Defendants have filed a
statement of defense generally denying the allegations and counterclaiming for
defamation relating to statements made by the Company about the litigation in
news releases. The parties have engaged in preliminary discovery, which includes
response to interrogatories, production of documents and request for further
production of documents. Management of the Company intends to aggressively
pursue and continue its legal actions and to further review its potential legal
remedies.
(c) On approximately October 3, 2002, the Company initiated litigation
against various broker-dealers, market makers and clearing agents (the U.S.
Defendants") allegedly involved in the Naked Short Sales by filing a Complaint
in the U.S. District Court for the District of Nevada, File No. S024914 (the
"United States Complaint"). The claims made by the Company against the U.S.
Defendants in the United States Complaint allege unlawful "shorting" activities
involving the Company's shares of common stock including fraud, negligence,
violation of U.S. securities laws, racketeering (RICO) and conspiracy. The
Company seeks an injunction against the U.S. Defendants to enjoin the unlawful
shorting activities and substantial damages, including punitive damages.
As of the date of this Quarterly Report, the U.S. Defendants have either
filed answers or requests for extensions of time within which to file formal
statements of defense. Management of the Company believes that upon receipt of
trading records and other documentation, the Company may amend the United States
Complaint to name additional broker-dealers, market makers, clearing agents and
individual securities professionals as defendants. The Company defeated a motion
to dismiss that was filed by certain defendants, which alleged the Company
lacked jurisdiction in the state of Nevada. Management of the Company intends to
aggressively pursue and continue its legal actions and to further review its
potential legal remedies.
Except as disclosed above, management is not aware of any other legal
proceedings contemplated by any governmental authority or other party involving
the Company or its properties. No director, officer or affiliate of the Company
is (i) a party adverse to the Company in any legal proceedings, or (ii) has an
adverse interest to the Company in any legal proceedings. Management, however,
is aware that the Securities and Exchange Commission filed a complaint in the
United States District Court for the District of Maryland naming Agora
Publishing and other defendants, which in the text of the complaint references
Mr. James D. Davidson. In consideration of complications and controversy
resulting from such litigation and the potential for negative investor
perceptions, on April 16, 2003, Mr. Davidson tendered his temporary resignation
as the Chief Financial Officer and a director of the Company. Management is not
aware of any other legal proceedings pending or that have been threatened
against the Company or its properties.
ITEM 2. CHANGES IN SECURITIES AND USE OF PROCEEDS
NON-QUALIFIED STOCK OPTION PLAN
On May 15, 2002, the Board of Directors unanimously approved and adopted a
stock option plan and on September 30, 2002, the Board of Directors approved the
adoption of a new stock option plan (the "Stock Option Plan"), which provides
authorization to the Board of Directors to grant up to 3,500,000 Stock Options
to directors, officers, employees and consultants of the Company and its
subsidiaries.
In accordance with the terms and provisions of the Stock Option Plan, and
as of the date of this Quarterly Report, the Board of Directors of the Company
has granted an aggregate of 3,270,000 stock options as follows: (i) 1,740,000
stock options and 395,000 incentive stock options exercisable at $1.00 per share
to previous holders of stock options of GeneMax Pharmaceuticals to replace stock
options previously granted by GeneMax Pharmaceuticals at $0.60 per share; (ii)
1,000,000 stock options at $0.50 per share to ICI and/or its employees or
consultants who, in such capacities, rendered bona fide services on behalf of
the Company including, but not limited to, administrative and managerial (which
shares were subject to an S-8 registration statement filed with the Securities
and Exchange Commission); (iii) 20,000 stock options at $5.50 per share; (iv)
15,000 stock options at $7.50 per share; and (v) 100,000 stock options at $8.50
per share. During the six-month period, the Company repriced 100,000 stock
options originally at $8.50, 20,000 stock options originally at $5.50 and 15,000
stock options originally at $7.50 all to a new exercise price of $1.75 per
share. Effective July 1, 2003, the Company granted a further 25,000 stock
options at an exercise price of $1.90 per share for a period of three years.
Of the 3,270,000 stock options granted, and as of the date of this
Quarterly Report: (i) 1,000,000 stock options have been exercised at $0.50 per
share for aggregate proceeds of $500,000 by employees or consultants of ICI in
accordance with the terms of the respective notice and agreement of exercise of
option; and (ii) 25,000 stock options have been exercised at $1.00 per share for
aggregate proceeds of $25,000 in accordance with the terms of the notice and
agreement of exercise of option. Management of the Company believes that such
services provided by the employees or consultants of ICI on behalf of the
Company did not include services which directly or indirectly promoted or
maintained a market for the Company's securities nor were rendered in connection
with the offer or sale of securities in a capital-raising transaction.
Therefore, in connection with the exercise of such stock options, 1,000,000
shares of common stock of the Company were issued to certain employees or
consultants of ICI who provided bona fide services to the Company under the
Consulting Services Agreement and 25,000 shares were issued to optionees.
On April 16, 2003, the Board of Directors of the Company unanimously
approved and ratified the adoption of an amendment to the Stock Option Plan,
which provides authorization to the Board of Directors to grant up to an
additional 2,245,000 stock options to directors, officers, employees and
consultants of the Company and its subsidiaries for an aggregate limit of
4,500,000 stock options.
Pursuant to Board of Director approval and ratification, the Company has
granted 300,000 stock options at an exercise price of $1.00 per common share to
International Market Trend AG or its employees or consultants who provide
services to the Company (which 300,000 stock options are subject to an S-8
registration statement filed with the Securities and Exchange Commission on
August 12, 2003). In connection with the grant of such stock options to and the
subsequent exercise by International Market Trend AG or its employees or
consultants, management of the Company believes that such bona fide services
provided by the employees or consultants to the Company do not include services
which directly or indirectly promote or maintain a market for the Company's
securities nor were rendered in connection with the offer or sale of securities
in a capital-raising transaction.
As of the date of this Quarterly Report, there are 16,813,519 shares of
common stock issued and outstanding.
________________________________________________________________________________
Title of Class Name and Address of Amount and Nature Percent of
Beneficial Owner of Class Class
________________________________________________________________________________
(1)(2)
Common Stock James D. Davidson 1,316,666 8.58%
321 S. St. Asaph Street
Alexandria, Virginia 22314
(1)(3)
Common Stock Ronald L. Handford 1,266,000 7.38%
3432 West 13th Avenue
Vancouver, British Columbia
Canada V5Y 1W1
(1)(4)
Common Stock 442668 B.C. Ltd. 3,270,465 21.73%
12596 23rd Avenue
Surrey, British Columbia
Canada V4A 2C2
(5)
Common Stock Dr. Karl Hellstrom 100,000 0.06%
720 Broadway
Seattle, Washington 98122
Common Stock Grant R. Atkins 0 0%
435 Martin Street, Suite 2000
Blaine, Washington 98230
(6)
Common Stock All current officers 6,103,131 34.00%
and directors as a group
(4 persons)
________________________________________________________________________________
(1)
These are restricted shares of common stock.
(2)
Mr. James Davidson is an initial founding shareholder of GeneMax
Pharmaceuticals. This figure includes (a) 788,333 shares of common stock held of
record by Mr. Davidson; (b) an aggregate of 500,000 shares of common stock held
of record by Mr. Davidson's two minor children, respectively, over which Mr.
Davidson has sole voting and disposition rights; (c) an assumption of the
exercise of an aggregate of 13,333 warrants exercisable into 13,333 shares of
common stock at the rate of $0.75 per share expiring on May 1, 2006; (d) an
assumption of the exercise by Mr. Davidson of an aggregate of 15,000 warrants
exercisable by Mr. Davidson into 15,000 shares of common stock at the rate of
$1.00 per share expiring December 1, 2005; and (e) an assumption of the exercise
by Mr. Davidson of an aggregate of 150,000 stock options to acquire 150,000
shares of common stock at $1.00 per share (which exercise rights expired on July
15, 2003 in accordance with the terms of the stock option plan pursuant to Mr.
Davidson's resignation as the Chief Financial Officer and a director of the
Company). As of the date of this Quarterly Report, no warrants nor stock options
have been exercised.
(3)
Mr. Ronald Handford is an initial founding shareholder of GeneMax
Pharmaceuticals. This figure includes (a) 808,000 shares of common stock held of
record by Mr. Handford; (b) 100,000 shares of common stock held of record by
Handford Management Inc. over which Mr. Handford has sole voting and disposition
rights; (c) an assumption of the exercise by Mr. Handford of an aggregate of
8,000 warrants into 8,000 shares of common stock at $0.75 per share expiring
December 1, 2005; and (d) an assumption of the exercise by Mr. Handford of an
aggregate of 350,000 stock options to acquire 350,000 shares of common stock at
$1.00 per share. On approximately May 4, 2003, the 325,000 shares of common
stock previously held of record by Aberdeen Holdings Limited and the 325,000
shares of common stock previously held of record by Latitude 32 Holdings Ltd.
were transferred to Mr. Handford as the holder of record. As of the date of this
Quarterly Report, no warrants nor stock options have been exercised.
(4)
Dr. Wilfred Jefferies is an initial founding shareholder of GeneMax
Pharmaceuticals. Dr. Jefferies has sole voting and disposition rights over the
2,770,465 shares of common stock held of record by 442668 B.C. Ltd. This figure
also includes an assumption of the exercise by Dr. Jefferies of an aggregate of
500,000 stock options to acquire 500,000 shares of common stock at $1.00 per
share. As of the date of this Quarterly Report, no stock options have been
exercised.
(5)
This figure includes the assumption of the exercise by Dr. Hellstrom of an
aggregate of 100,000 stock options to acquire 100,000 shares of common stock at
$8.50 per shares (which have been repriced to $1.75 per share). As of the date
of this Quarterly Report, 56,250 stock options have vested and the remaining
stock options will vest or the next twenty-one months. As of the date of this
Quarterly Report, no stock options have been exercised.
(6)
This figure includes the assumption of the exercise of an aggregate of 36,333
warrants into 36,333 shares of common stock and the assumption of the exercise
of 1,100,000 stock options into 1,100,000 shares of common stock.
Notwithstanding the Pooling Agreement, there are no arrangements or
understanding among the entities and individuals referenced above or their
respective associates concerning election of directors or any other matters
which may require shareholder approval.
ITEM 3. DEFAULTS UPON SENIOR SECURITIES
No report required.
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
No report required.
ITEM 5. OTHER INFORMATION
No report required.
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K
Exhibits:
31.1 Form 302 Certification - CEO
31.2 Form 302 Certification - CFO
32.1 Form 906 Certification - CEO
32.2 Form 906 Certification - CFO
Reports on Form 8-K:
None.
SIGNATURES
In accordance with the requirements of the Exchange Act, the registrant
caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
GENEMAX CORP.
Dated: August 13, 2003 By: /s/ RONALD L. HANDFORD
_________________________________
President/Chief Executive Officer
Dated: August 13, 2003 By: /s/ GRANT R. ATKINS
_________________________________
Chief Financial Officer